Lilly to Acquire Novartis Animal Health - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Lilly to Acquire Novartis Animal Health



Eli Lilly and Company will acquire Novartis Animal Health for approximately $5.4 billion in an all-cash transaction that will expand Lilly's animal health business, Elanco. Upon completion of the acquisition,Elanco will be the second-largest animal health company in terms of global revenue. Lilly will acquire Novartis Animal Health's nine manufacturing sites, six research and development facilities, a portfolio of approximately 600 products, a pipeline with more than 40 projects in development, and over 3000 employees.

Lilly plans to fund this acquisition with approximately $3.4 billion of cash-on-hand and $2 billion in debt to be issued. No other financial terms of the transaction are being disclosed. The transaction is expected to close by the end of the first quarter of 2015, subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, similar requirements outside the US, and other customary closing conditions. The transaction is not subject to any financing conditions.

With this acquisition, Lilly expects to save an estimated $200 million per year within the first three years of the deal closing, adding up to more than 10% of operating expenses from the combined animal health businesses.

The acquisition will expand Elanco's product portfolio, R&D and manufacturing capabilities, and commercial presence. In addition, Elanco will have a greater presence in the animal and swine markets, the equine and vaccines areas, and the aquaculture market.

Source: Eli Lilly and Company

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here